Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 24Gastrointestinal 16Genitourinary 13Other 8Other hematologic neoplasm 6Head & Neck 6Thoracic 5Lymphoid 5Plasma cell 4Gynecologic 4CNS 4Tumor-Agnostic 2Sarcoma 2Endocrine 2Other solid neoplasm 1Myeloid 1Dermatologic 1

Conditions

Neoplasms 2

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 48Radiotherapy 39Magnetic Resonance Spectroscopy 35pembrolizumab 31Gemcitabine 30Bevacizumab 30Nivolumab 29Carboplatin 29Radiosurgery 27Standard of Care 26Oxaliplatin 26Capecitabine 25Paclitaxel 24Interviews as Topic 24Cisplatin 24Fluorouracil 23Erlotinib Hydrochloride 22Everolimus 19Irinotecan 18Trastuzumab 17Methods 17Exercise 17Docetaxel 17Biopsy 17Cyclophosphamide 16Educational Status 15Sorafenib 14Ipilimumab 14Fluorodeoxyglucose F18 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Resistance Training × Tumor-Agnostic × Clear all
NCT07159815 2026-06-01

REACT

Inland Norway University of Applied Sciences

Phase NA Active not recruiting
160 enrolled
Tumor-Agnostic

Neoplasms

NCT00798200 2016-03-03

CanWell

McMaster University

Phase 1 Completed
200 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡